Strain Data Sheet

RBRC01236

Strain Information

Image
BRC No.RBRC01236
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameSTOCK Ahr<tm1Yfk> Nfe2l2<tm1Mym>
Former Common nameNrf2(+/-)::AhR(+/-) compound mouse
H-2 Haplotype
ES Cell line
Background strain
Appearance
Strain development
Strain description
Colony maintenance
References
An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y
Biochem. Biophys. Res. Commun., 236, 313-322 (1997). 9240432

Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor.
Mimura J, Yamashita K, Nakamura K, Morita M, Takagi T N, Nakao K, Ema M, Sogawa K, Yasuda M, Katsuki M, Fujii-Kuriyama Y
Genes Cells, 2, 645-654 (1997). 9427285

Gene expression of detoxifying enzymes in AhR and Nrf2 compound null mutant mouse.
Noda S, Harada N, Hida A, Fujii-Kuriyama Y, Motohashi H, Yamamoto M
Biochem. Biophys. Res. Commun., 303, 105-111 (2003). 12646173

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Ahr
MGI:105043
aryl-hydrocarbon receptor12Ahr<tm1Yfk> targeted mutation 1, Yoshiaki Fujii-Kuriyama
  • retinitis pigmentosa 85(MedGEN)
  • lacZ beta-galactosidase (E. coli)12
    neo neomycin resistance gene (E. coli)12 herpes simplex virus thymidine kinase promoter (HSV tk promoter)
    nls SV40 large T antigen nuclear localization signal (NLS)12nls
    Nfe2l2
    MGI:108420
    nuclear factor, erythroid derived 2, like 22Nfe2l2<tm1Mym>
    MGI:2385925
    targeted mutation 1, Masayuki Yamamoto
  • immunodeficiency, developmental delay, and hypohomocysteinemia(MedGEN)
  • lacZ beta-galactosidase (E. coli)2
    neo neomycin resistance gene (E. coli)2 herpes simplex virus thymidine kinase promoter (HSV tk promoter)
    nls SV40 large T antigen nuclear localization signal (NLS)2nls

    Phenotype

    Annotation by Mammalian phenotyhpe ontology
  • abnormal behavior(MP:0004924)

  • abnormal enamel morphology(MP:0002576)

  • abnormal glomerular capillary morphology(MP:0011320)

  • abnormal glomerular mesangium morphology(MP:0011339)

  • abnormal horizontal vestibuloocular reflex(MP:0011042)
  • more 63 phenotypes
  • abnormal incisor color(MP:0010096)

  • abnormal iron homeostasis(MP:0005637)

  • abnormal iron level(MP:0001770)

  • abnormal leukocyte adhesion(MP:0003628)

  • abnormal macrophage physiology(MP:0002451)

  • abnormal optokinetic reflex(MP:0009619)

  • abnormal physiological response to xenobiotic(MP:0008872)

  • abnormal renal glomerulus morphology(MP:0005325)

  • abnormal respiratory system physiology(MP:0002133)

  • abnormal tooth morphology(MP:0002100)

  • abnormal urinary bladder morphology(MP:0000538)

  • abnormal urinary bladder urothelium morphology(MP:0000540)

  • abnormal urinary bladder vasculature morphology(MP:0011773)

  • abnormal xenobiotic pharmacokinetics(MP:0008875)

  • ameloblast degeneration(MP:0000129)

  • cachexia(MP:0005150)

  • circling(MP:0001394)

  • cystolithiasis(MP:0011625)

  • decreased CD4-positive, alpha-beta T cell number(MP:0008075)

  • decreased T cell number(MP:0005018)

  • decreased body weight(MP:0001262)

  • decreased physiological sensitivity to xenobiotic(MP:0008874)

  • decreased urine creatinine level(MP:0011471)

  • disorganized retina layers(MP:0001328)

  • enlarged lymph nodes(MP:0000702)

  • glomerular crescent(MP:0011506)

  • glomerulonephritis(MP:0002743)

  • glomerulosclerosis(MP:0005264)

  • hepatic steatosis(MP:0002628)

  • hypoglycemia(MP:0000189)

  • increased IgG level(MP:0002493)

  • increased IgM level(MP:0002494)

  • increased acute inflammation(MP:0005088)

  • increased anti-double stranded DNA antibody level(MP:0004762)

  • increased anti-nuclear antigen antibody level(MP:0004794)

  • increased cerebral infarct size(MP:0006060)

  • increased circulating alanine transaminase level(MP:0002941)

  • increased circulating interleukin-6 level(MP:0008596)

  • increased circulating tumor necrosis factor level(MP:0008553)

  • increased hepatocyte apoptosis(MP:0003887)

  • increased incidence of tumors by chemical induction(MP:0004499)

  • increased kidney cell proliferation(MP:0011440)

  • increased liver iron level(MP:0008807)

  • increased lung weight(MP:0005630)

  • increased mesangial cell number(MP:0011427)

  • increased spleen weight(MP:0004952)

  • increased stomach tumor incidence(MP:0010301)

  • increased susceptibility to experimental autoimmune uveoretinitis(MP:0004821)

  • increased susceptibility to induced colitis(MP:0008537)

  • increased susceptibility to ischemic brain injury(MP:0003076)

  • increased susceptibility to xenobiotic induced morbidity/mortality(MP:0009766)

  • increased urinary bladder carcinoma incidence(MP:0009550)

  • increased urine protein level(MP:0002962)

  • increased urine uric acid level(MP:0009810)

  • liver inflammation(MP:0001860)

  • lung inflammation(MP:0001861)

  • oxidative stress(MP:0003674)

  • postnatal growth retardation(MP:0001732)

  • premature death(MP:0002083)

  • pulmonary fibrosis(MP:0006050)

  • urinary bladder fibrosis(MP:0011769)

  • urinary bladder inflammation(MP:0009646)

  • weight loss(MP:0001263)
  • Detailed phenotype data

    Ordering Information

    Donor DNASimian virus 40 Large T antigen nuclear localization signal (NLS), E. coli lacZ, herpes simplex virus thymidine kinase promoter (HSV tk promoter), E. coli neo, mouse Nrf2 genomic DNA, mouse Ahr genomic DNA, SV40 T antigen intron and polyadenylation signal
    Research applicationCell Biology Research
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Noda S.et al. (2003) BIochem Biophys Res Commun. 303:105-111.In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The RECIPIENT agrees to include the DEPOSITOR/DEVELOPER as a co-author in any publications resulted by the use of the BIOLOGICAL RESOURCE during the first 2 years after deposition by the DEPOSITOR to the RIKEN BRC. The RECIPIENT should contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE.
    DepositorMasayuki Yamamoto (University of Tsukuba)
    Strain Statusan icon for Frozen embryosFrozen embryos
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. Acceptance of responsibility for living modified organism (Japanese / English)
    Lab HP (Japanese)

    BRC mice in Publications

    No Data